Ridaforolimus Eluting Stent System

EluNIR™

A pioneer in cardiovascular intervention for 25 years, Medinol raises the bar once again with the introduction of the EluNIR elastomeric Drug-Eluting Stent — a category-of-one innovation purposefully designed to meet the unique demands of the the ever-changing vascular environment.

Dotter has launched this innovative device in the Korean market by acquiring the rights to sell the product from Medinol.

labling Document

EluNIR™ Ridaforolimus Eluting Stent System

  • Excellent clinical outcomes
  • Redefining deliverability with a new spring tip
  • Low footprint cobalt-chromium design
  • Optimal conformability and vessel support
  • Elastomeric coating and outstanding surface integrity
  • Eluting Ridaforolimus, a high therapeutic index limus drug

WiZeCell™

EluNIR’s variable width design uses ultra narrow “Z” struts that provide flexibility and conformability while narrow “W” struts provide excellent radial strength.

Optimized side branch access allows treating larger bifurcations.

  • EluNIR’s adaptive cell size prevents tissue prolapse, strut overlap and provides uniform scaffolding even on a curved vessel
  • The ultimate balance between conformability, scaffolding and vessel support

Flexx2 - Incomparable deliverability

EluNIR’s Flexx2 delivery system integrates a tapered spring tip and reinforced hypotube for improved:

Flexibility

Deliverability even through tortuosity, calcification and previously implanted stents

Pushability

The metallic spring tip leverages the high system-pushability for enhanced crossability

Trackability

Tapered spring tip closely tracks the wire to help prevent fish mouthing and buckling common to plastic tips of other stent systems

Labeling document (Korean)

Get In touch

info@dotter.com

Inquiries about products or suggestions for partnerships
are always welcome

phone  +82.32.258.5448
Fax +82.32.258.5449